The researchers also conducted brain scans of the participants for once a month over the next six months and were given the MS drug interferon beta-1a for a year after which they were free to take the MS drug recommended by their neurologist. After a period of five years, the researchers found that around 58 percent of those who had been given the vaccine had not developed MS compared to 30 percent of those who received the placebo.
"These results are promising, but much more research needs to be done to learn more about the safety and long-term effects of this live vaccine. Doctors should not start using this vaccine to treat MS or clinically isolated syndrome", lead researcher Giovanni Ristori said.
Source: Medindia